193 related articles for article (PubMed ID: 27387766)
1. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents.
Mhaskar R; Djulbegovic B
JAMA Oncol; 2016 Nov; 2(11):1499-1500. PubMed ID: 27387766
[TBL] [Abstract][Full Text] [Related]
2. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
3. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
4. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
Shord SS; Hamilton JM; Cuellar S
J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
[TBL] [Abstract][Full Text] [Related]
5. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
J Cancer Res Clin Oncol; 2012 Feb; 138(2):179-87. PubMed ID: 21972052
[TBL] [Abstract][Full Text] [Related]
6. The addition of oral iron improves chemotherapy-induced anemia in patients receiving erythropoiesis-stimulating agents.
Tan J; Du S; Zang X; Ding K; Ginzburg Y; Chen H
Int J Cancer; 2022 Nov; 151(9):1555-1564. PubMed ID: 35639027
[TBL] [Abstract][Full Text] [Related]
7. Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.
Szucs TD; Blank PR; Schwenkglenks M; Aapro M
Oncology; 2011; 81(1):45-9. PubMed ID: 21921645
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced anemia at an urban academic medical center: iron studies and supplementation.
Shord SS; Cuellar S
J Am Pharm Assoc (2003); 2008; 48(4):487-93. PubMed ID: 18653424
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
[TBL] [Abstract][Full Text] [Related]
11. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
12. Managing Chemotherapy-Induced Anemia with Erythropoiesis-Stimulating Agents Plus Iron.
Whitehead L
Am J Nurs; 2017 May; 117(5):67. PubMed ID: 28448368
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL; Larholt K; Fraser KA; McKenzie RS; Senbetta M; Piech CT
Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
15. Update on safety of ESAs in cancer-induced anemia.
Glaspy J
J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
[TBL] [Abstract][Full Text] [Related]
16. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
18. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]